152 related articles for article (PubMed ID: 16939522)
1. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation.
Marier JF; Lor M; Morin J; Roux L; Di Marco M; Morelli G; Saedder EA
Br J Clin Pharmacol; 2007 Jan; 63(1):121-4. PubMed ID: 16939522
[TBL] [Abstract][Full Text] [Related]
2. Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent.
Kress HG; Boss H; Delvin T; Lahu G; Lophaven S; Marx M; Skorjanec S; Wagner T
Eur J Pharm Biopharm; 2010 Jun; 75(2):225-31. PubMed ID: 20152899
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects.
Marier JF; Lor M; Potvin D; Dimarco M; Morelli G; Saedder EA
J Clin Pharmacol; 2006 Jun; 46(6):642-53. PubMed ID: 16707411
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A
Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications.
Sathyan G; Guo C; Sivakumar K; Gidwani S; Gupta S
Curr Med Res Opin; 2005 Dec; 21(12):1961-8. PubMed ID: 16368047
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers.
Liu J; Zhou X
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):175-80. PubMed ID: 24424109
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers.
Lorch U; Pierscionek T; Freier A; Spencer CS; Täubel J
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):260-271. PubMed ID: 32748570
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence and safety of a novel fentanyl transdermal matrix system compared with a transdermal reservoir system.
Moore KT; Adams HD; Natarajan J; Ariyawansa J; Richards HM
J Opioid Manag; 2011; 7(2):99-107. PubMed ID: 21561033
[TBL] [Abstract][Full Text] [Related]
9. Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study.
Nave R; Connolly SM; Popper L; Lahu G; Schmitt H
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):751-9. PubMed ID: 22943926
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat.
Ashburn MA; Ogden LL; Zhang J; Love G; Basta SV
J Pain; 2003 Aug; 4(6):291-7. PubMed ID: 14622685
[TBL] [Abstract][Full Text] [Related]
11. The transdermal delivery of fentanyl.
Lane ME
Eur J Pharm Biopharm; 2013 Aug; 84(3):449-55. PubMed ID: 23419814
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.
Freise KJ; Newbound GC; Tudan C; Clark TP
J Vet Pharmacol Ther; 2012 Aug; 35 Suppl 2():27-33. PubMed ID: 22731773
[TBL] [Abstract][Full Text] [Related]
13. Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain.
Hoy SM; Keating GM
Drugs; 2008; 68(12):1711-21. PubMed ID: 18681493
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration.
Sathyan G; Jaskowiak J; Evashenk M; Gupta S
Clin Pharmacokinet; 2005; 44 Suppl 1():7-15. PubMed ID: 16156111
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain.
Saito T; Fujii M; Saito S; Shimada K; Fujiwara K; Kobayashi K
Oncology; 2014; 86(1):10-5. PubMed ID: 24335580
[TBL] [Abstract][Full Text] [Related]
16. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics.
Darwish M; Kirby M; Robertson P; Hellriegel E; Jiang JG
Clin Pharmacokinet; 2006; 45(8):843-50. PubMed ID: 16884321
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
[TBL] [Abstract][Full Text] [Related]
18. Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS).
Gupta SK; Hwang S; Southam M; Sathyan G
Clin Pharmacokinet; 2005; 44 Suppl 1():25-32. PubMed ID: 16156113
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Lennernäs B; Hedner T; Holmberg M; Bredenberg S; Nyström C; Lennernäs H
Br J Clin Pharmacol; 2005 Feb; 59(2):249-53. PubMed ID: 15676050
[TBL] [Abstract][Full Text] [Related]
20. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
